<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693548</url>
  </required_header>
  <id_info>
    <org_study_id>SAFEHEART</org_study_id>
    <nct_id>NCT02693548</nct_id>
  </id_info>
  <brief_title>The Spanish Familial Hypercholesterolaemia Cohort Study</brief_title>
  <acronym>SAFEHEART</acronym>
  <official_title>The Spanish Familial Hypercholesterolaemia Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Hipercolesterolemia Familiar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Hipercolesterolemia Familiar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SAFEHEART is a large, on-going registry study in molecularly defined patients with
      heterozygous FH treated in Spain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familiar hypercholesterolemia (FH) is the most common genetic disorder associated with the
      development of severe and premature coronary artery disease (CAD). The disorder is caused by
      mutations in the gene that encodes the low-density lipoprotein receptor (LDL-r), resulting in
      a lower expression of functional LDL-r in the liver. FH has autosomal dominant transmission
      with high penetrance and the prevalence of heterozygous individuals is one in 400 to 500 in
      the general population. To date, more than 800 different functional mutations of the LDL-r
      gene have been described worldwide, and more than 200 have been documented in Spain. In
      addition, a much less common disorder that resemble FH is familial defective apoB 100
      disorder (FDB) produced by a mutation in the Apo B 100 gene. FDB accounts for a significant
      proportion of FH in some localized regions of Spain.

      Life expectancy is shortened by 20 to 30 years in FH patients, and sudden death and
      myocardial infarction are the principal causes of death. The Simon Broome Register of FH in
      Great Britain, has shown that FH has a 100-fold increase in coronary mortality and a nearly
      10-fold increase in total mortality, especially in young adults.

      Since the 1990's, coronary mortality and total mortality in FH patients have decreased
      remarkably in part due to the use of more effective lipid-lowering therapy such as statins.
      The analysis of the Dutch FH cohort showed that an early treatment with statins after the
      diagnosis of the disorder leads to near normalisation of coronary heart disease risk
      comparable to the general population. Therefore, most of patients require an early,
      continuous and more intensive lipid-lowering therapy.

      Despite the use of statins, this population still have a high risk for the development of
      premature CAD. Therefore, the need to study the relatives of a known FH case, know as cascade
      screening, is essential to detect those cases that are younger, probably with a less severe
      form of FH and are not receiving treatment to prevent cardiovascular disease development.

      Although the genetic defect is probably the most important factor in the clinical expression
      of FH, other genetic (gene-gene interactions), environmental (particularly those relating to
      diet, tobacco consumption and physical activity) and metabolic factors could play an
      important role in modulating the atherosclerotic burden in this population.

      To gain insight into the prognostic factors and mechanisms that influence the development of
      CAD and mortality in FH, a long-term prospective follow-up of a molecularly well-defined FH
      cohort using a multidisciplinary approach is necessary. This cohort is an excellent tool of
      translational research to evaluate and determine the principal prognostic factors related to
      CAD morbidity and mortality.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic assessment: time to fatal or non-fatal cardiovascular event.</measure>
    <time_frame>up to 12 years</time_frame>
    <description>Time to first cardiovascular event: fatal or non-fatal myocardial infarction, fatal or non-fatal ischemic stroke, coronary revascularization, peripheral artery revascularization, aortic valve replacement or cardiovascular death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol level (mg/dl) at entry and at follow-up</measure>
    <time_frame>up to12 years</time_frame>
    <description>LDL-cholesterol measurement at enrolment and after follow-up. At enrolment, a central core lab is in charge of the analysis. During follow-up, a yearly-based phone call is used to contact every subject and a complete lipid profile is obtained from the patient (obtained in his/her usual medical care).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4141</enrollment>
  <condition>Familial Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>Familial hypercholesterolaemia patients</arm_group_label>
    <description>Index cases with genetic diagnosis of FH and their relatives over 15 years old with a genetic diagnosis of FH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unaffected relatives</arm_group_label>
    <description>Relatives of FH patients without FH (genetically defined)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood samples were taken after 12 hours of fasting. Serum, plasma and DNA samples were
      aliquoted and preserved at -80°C. Serum total cholesterol, triglycerides and HDL-cholesterol
      levels were measured in a centralized laboratory using enzymatic methods
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Index cases with genetic diagnosis of FH and their relatives over 15 years old with a
        genetic diagnosis of FH and their unaffected relatives
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Index cases with genetic diagnosis of FH and their relatives over 15 years old with a
             genetic diagnosis of FH and their first-degree relatives

        Exclusion Criteria:

          -  Patient unwillingness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Mata, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fundacion Hipercolesterolemia Familiar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Mata, MD</last_name>
    <phone>0034915570071</phone>
    <email>pmata@colesterolfamiliar.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leopoldo Perez de Isla, MD</last_name>
    <phone>0034609084225</phone>
    <email>leopisla@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundacion Hipercolesterolemia Familiar</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Mata, MD</last_name>
      <phone>0034915 570 071</phone>
      <email>fhfsecretaria@colesterolfamiliar.org</email>
    </contact>
    <contact_backup>
      <last_name>Leopoldo Perez de Isla, MD</last_name>
      <phone>0034609084225</phone>
      <email>leopisla@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos RD, Soran H, Watts GF, Abifadel M, Aguilar-Salinas CA, Akram A, Alnouri F, Alonso R, Al-Rasadi K, Banach M, Bogsrud MP, Bourbon M, Bruckert E, Car J, Corral P, Descamps O, Dieplinger H, Durst R, Freiberger T, Gaspar IM, Genest J, Harada-Shiba M, Jiang L, Kayikcioglu M, Lam CS, Latkovskis G, Laufs U, Liberopoulos E, Nilsson L, Nordestgaard BG, O'Donoghue JM, Sahebkar A, Schunkert H, Shehab A, Stoll M, Su TC, Susekov A, Widén E, Catapano AL, Ray KK. Familial hypercholesterolaemia: A global call to arms. Atherosclerosis. 2015 Nov;243(1):257-9. doi: 10.1016/j.atherosclerosis.2015.09.021. Epub 2015 Sep 18.</citation>
    <PMID>26408930</PMID>
  </reference>
  <reference>
    <citation>Fuentes F, Alcala-Diaz JF, Watts GF, Alonso R, Muñiz O, Díaz-Díaz JL, Mata N, Sanchez Muñoz-Torrero JF, Brea Á, Galiana J, Figueras R, Aguado R, Piedecausa M, Cepeda JM, Vidal JI, Rodríguez-Cantalejo F, López-Miranda J, Mata P; SAFEHEART Investigators. Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. Int J Cardiol. 2015 Dec 15;201:79-84. doi: 10.1016/j.ijcard.2015.07.107. Epub 2015 Aug 5.</citation>
    <PMID>26296047</PMID>
  </reference>
  <reference>
    <citation>Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Ordovás JM, Mata P; SAFEHEART Investigators. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014 May 20;63(19):1982-9. doi: 10.1016/j.jacc.2014.01.063. Epub 2014 Mar 13.</citation>
    <PMID>24632281</PMID>
  </reference>
  <reference>
    <citation>Alonso R, Mata P, Zambón D, Mata N, Fuentes-Jiménez F. Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes. Expert Rev Cardiovasc Ther. 2013 Mar;11(3):327-42. doi: 10.1586/erc.13.7. Review.</citation>
    <PMID>23469913</PMID>
  </reference>
  <reference>
    <citation>Aledo R, Alonso R, Mata P, Llorente-Cortés V, Padró T, Badimon L. LRP1 gene polymorphisms are associated with premature risk of cardiovascular disease in patients with familial hypercholesterolemia. Rev Esp Cardiol (Engl Ed). 2012 Sep;65(9):807-12. Epub 2012 Jul 20. English, Spanish.</citation>
    <PMID>22819221</PMID>
  </reference>
  <reference>
    <citation>Vázquez C, Alonso R, Garriga M, de Cos A, de la Cruz JJ, Fuentes-Jiménez F, Salas-Salvadó J, Mata P. Validation of a food frequency questionnaire in Spanish patients with familial hypercholesterolaemia. Nutr Metab Cardiovasc Dis. 2012 Oct;22(10):836-42. doi: 10.1016/j.numecd.2011.01.007. Epub 2011 Jun 23.</citation>
    <PMID>21703832</PMID>
  </reference>
  <reference>
    <citation>Mata N, Alonso R, Badimón L, Padró T, Fuentes F, Muñiz O, Perez-Jiménez F, López-Miranda J, Díaz JL, Vidal JI, Barba A, Piedecausa M, Sanchez JF, Irigoyen L, Guallar E, Ordovas JM, Mata P. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis. 2011 Jun 10;10:94. doi: 10.1186/1476-511X-10-94.</citation>
    <PMID>21663647</PMID>
  </reference>
  <reference>
    <citation>Criado-García J, Fuentes F, Cruz-Teno C, García-Rios A, Jiménez-Morales A, Delgado-Lista J, Mata P, Alonso R, López-Miranda J, Pérez-Jiménez F; Spanish Group for the Study of Familiar Hypercholesterolemia. R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study. Lipids Health Dis. 2011 Apr 9;10:50. doi: 10.1186/1476-511X-10-50.</citation>
    <PMID>21477332</PMID>
  </reference>
  <reference>
    <citation>Garcia-Rios A, Perez-Martinez P, Mata P, Fuentes F, Lopez-Miranda J, Alonso R, Caballero J, Mata N, Perez-Jimenez F, Ordovas JM. Polymorphism at the TRIB1 gene modulates plasma lipid levels: insight from the Spanish familial hypercholesterolemia cohort study. Nutr Metab Cardiovasc Dis. 2011 Dec;21(12):957-63. doi: 10.1016/j.numecd.2010.04.002. Epub 2010 Aug 6.</citation>
    <PMID>20692138</PMID>
  </reference>
  <reference>
    <citation>Zambón D, Quintana M, Mata P, Alonso R, Benavent J, Cruz-Sánchez F, Gich J, Pocoví M, Civeira F, Capurro S, Bachman D, Sambamurti K, Nicholas J, Pappolla MA. Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med. 2010 Mar;123(3):267-74. doi: 10.1016/j.amjmed.2009.08.015.</citation>
    <PMID>20193836</PMID>
  </reference>
  <reference>
    <citation>Garcia-Rios A, Perez-Martinez P, Fuentes F, Mata P, Lopez-Miranda J, Alonso R, Rodriguez F, Garcia-Olid A, Ruano J, Ordovas JM, Perez-Jimenez F. Genetic variations at ABCG5/G8 genes modulate plasma lipids concentrations in patients with familial hypercholesterolemia. Atherosclerosis. 2010 Jun;210(2):486-92. doi: 10.1016/j.atherosclerosis.2010.01.010. Epub 2010 Jan 22.</citation>
    <PMID>20172523</PMID>
  </reference>
  <reference>
    <citation>Alonso R, Defesche JC, Tejedor D, Castillo S, Stef M, Mata N, Gomez-Enterria P, Martinez-Faedo C, Forga L, Mata P. Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. Clin Biochem. 2009 Jun;42(9):899-903. doi: 10.1016/j.clinbiochem.2009.01.017. Epub 2009 Feb 6.</citation>
    <PMID>19318025</PMID>
  </reference>
  <reference>
    <citation>Alonso R, Mata N, Castillo S, Fuentes F, Saenz P, Muñiz O, Galiana J, Figueras R, Diaz JL, Gomez-Enterría P, Mauri M, Piedecausa M, Irigoyen L, Aguado R, Mata P; Spanish Familial Hypercholesterolaemia Group. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis. 2008 Oct;200(2):315-21. doi: 10.1016/j.atherosclerosis.2007.12.024. Epub 2008 Feb 20.</citation>
    <PMID>18243212</PMID>
  </reference>
  <reference>
    <citation>Meriño-Ibarra E, Castillo S, Mozas P, Cenarro A, Martorell E, Díaz JL, Suárez-Tembra M, Alonso R, Civeira F, Mata P, Pocoví M; Spanish Group of Familial Hypercholesterolemia. Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Hum Biol. 2005 Oct;77(5):663-73.</citation>
    <PMID>16596945</PMID>
  </reference>
  <reference>
    <citation>Civeira F, Castillo S, Alonso R, Meriño-Ibarra E, Cenarro A, Artied M, Martín-Fuentes P, Ros E, Pocoví M, Mata P; Spanish Familial Hypercholesterolemia Group. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1960-5. Epub 2005 Jul 14.</citation>
    <PMID>16020744</PMID>
  </reference>
  <reference>
    <citation>Alonso R, Castillo S, Civeira F, Puzo J, de la Cruz JJ, Pocoví M, Mata P. [Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases]. Med Clin (Barc). 2002 Apr 13;118(13):487-92. Spanish.</citation>
    <PMID>11975885</PMID>
  </reference>
  <reference>
    <citation>Castillo S, Tejedor D, Mozas P, Reyes G, Civeira F, Alonso R, Ros E, Pocoví M, Mata P. The apolipoprotein B R3500Q gene mutation in Spanish subjects with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis. 2002 Nov;165(1):127-35.</citation>
    <PMID>12208478</PMID>
  </reference>
  <reference>
    <citation>Alonso R, Mata P, De Andres R, Villacastin BP, Martínez-González J, Badimon L. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis. 2001 Aug;157(2):423-9.</citation>
    <PMID>11472743</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial Hypercholesterolaemia</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Available access for publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

